213 related articles for article (PubMed ID: 29874689)
1. Pharmacodynamic Effects of a 6-Hour Regimen of Enoxaparin in Patients Undergoing Primary Percutaneous Coronary Intervention (PENNY PCI Study).
Sumaya W; Parker WAE; Fretwell R; Hall IR; Barmby DS; Richardson JD; Iqbal J; Adam Z; Morgan KP; Gunn JP; Mason AE; Judge HM; Gale CP; Ajjan RA; Storey RF
Thromb Haemost; 2018 Jul; 118(7):1250-1256. PubMed ID: 29874689
[TBL] [Abstract][Full Text] [Related]
2. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341
[TBL] [Abstract][Full Text] [Related]
3. Early P2Y12 Inhibitors Escalation in Primary PCI Patients: Insights from the RENOVAMI Registry.
Lupi A; Bona RD; Meliga E; Capodanno D; Schaffer A; Bongo AS; Gaudio G; Guasti L; Alexopoulos D; Valgimigli M; Porto I
Thromb Haemost; 2018 May; 118(5):852-863. PubMed ID: 29618159
[TBL] [Abstract][Full Text] [Related]
4. Observational Study of Platelet Reactivity in Patients Presenting With ST-Segment Elevation Myocardial Infarction Due to Coronary Stent Thrombosis Undergoing Primary Percutaneous Coronary Intervention: Results From the European PREvention of Stent Thrombosis by an Interdisciplinary Global European Effort Registry.
Godschalk TC; Byrne RA; Adriaenssens T; Malik N; Feldman LJ; Guagliumi G; Alfonso F; Neumann FJ; Trenk D; Joner M; Schulz C; Steg PG; Goodall AH; Wojdyla R; Dudek D; Wykrzykowska JJ; Hlinomaz O; Zaman AG; Curzen N; Dens J; Sinnaeve P; Desmet W; Gershlick AH; Kastrati A; Massberg S; Ten Berg JM;
JACC Cardiovasc Interv; 2017 Dec; 10(24):2548-2556. PubMed ID: 29268884
[TBL] [Abstract][Full Text] [Related]
5. Influence of intravenous fentanyl compared with morphine on ticagrelor absorption and platelet inhibition in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the PERSEUS randomized trial.
Degrauwe S; Roffi M; Lauriers N; Muller O; Masci PG; Valgimigli M; Iglesias JF
Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):158-163. PubMed ID: 30101278
[TBL] [Abstract][Full Text] [Related]
6. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
[TBL] [Abstract][Full Text] [Related]
7. Time-dependent benefits of pre-treatment with new oral P2Y
Pepe M; Cafaro A; Paradies V; Signore N; Addabbo F; Bortone AS; Navarese EP; Contegiacomo G; Forleo C; Bartolomucci F; Di Cillo O; Bianchi FP; Zanna D; Favale S
Catheter Cardiovasc Interv; 2019 Mar; 93(4):592-601. PubMed ID: 30269413
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of prasugrel administration immediately after percutaneous coronary intervention in ST-elevation myocardial infarction.
Flierl U; Zauner F; Sieweke JT; Berliner C; Napp LC; Tillmanns J; Bauersachs J; Schäfer A
Thromb Haemost; 2017 Jan; 117(1):99-104. PubMed ID: 27734075
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of P2Y12 receptor antagonists on platelet function and clinical outcomes in patients undergoing Primary PCI: A substudy of the HEAT-PPCI trial.
Shahzad A; Khanna V; Kemp I; Shaw M; Mars C; Cooper R; Wilson K; Curzen N; Stables RH
EuroIntervention; 2018 Mar; 13(16):1931-1938. PubMed ID: 29336311
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Tang X; Li R; Jing Q; Wang Q; Liu P; Zhang P; Liu Y
J Cardiovasc Pharmacol; 2016 Aug; 68(2):115-20. PubMed ID: 27010809
[TBL] [Abstract][Full Text] [Related]
11. Impact of platelet inhibition level on subsequent no-reflow in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Aitmokhtar O; Paganelli F; Benamara S; Azaza A; Bonello L; Hamza O; Seddiki S; Benathmane T; Saidane M; Bouzid A; Kara M; Sik A; Azzouz A; Harbi F; Monsuez JJ; Benkhedda S
Arch Cardiovasc Dis; 2017 Nov; 110(11):626-633. PubMed ID: 28583820
[TBL] [Abstract][Full Text] [Related]
12. Point of care platelet activity measurement in primary PCI [PINPOINT-PPCI]: a protocol paper.
Johnson TW; Marsden D; Mumford A; Pike K; Mundell S; Butler M; Strange JW; Bowles R; Rogers C; Baumbach A; Reeves BC
BMC Cardiovasc Disord; 2014 Apr; 14():44. PubMed ID: 24708700
[TBL] [Abstract][Full Text] [Related]
13. Effect of postprocedural full-dose infusion of bivalirudin on acute stent thrombosis in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Outcomes in a large real-world population.
Wang H; Liang Z; Li Y; Li B; Liu J; Hong X; Lu X; Wu J; Zhao W; Liu Q; An J; Li L; Pu F; Ming Q; Han Y
Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28083915
[TBL] [Abstract][Full Text] [Related]
14. Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial).
Madan M; Radhakrishnan S; Reis M; Paradiso-Hardy FL; Godin-Edgecombe M; Sparling C; Phillips AM; Shanmugasegaram S; Fort S; Naqvi SZ; Cohen EA
Am J Cardiol; 2005 Jun; 95(11):1295-301. PubMed ID: 15904632
[TBL] [Abstract][Full Text] [Related]
15. Should STEMI Patients Receive Opiate Analgesia? The Morphine Paradox.
Farag M; Spinthakis N; Srinivasan M; Gorog DA
Curr Vasc Pharmacol; 2018; 16(5):477-483. PubMed ID: 29345594
[TBL] [Abstract][Full Text] [Related]
16. How Long Does It Take for Clopidogrel and Ticagrelor to Inhibit Platelets in Patients Undergoing Primary Percutaneous Coronary Intervention? A Detailed Pharmacodynamic Analysis: Time Course of Platelet Reactivity in STEMI (TOPS).
Bergmeijer TO; Godschalk TC; Janssen PWA; Berge KVD; Breet NJ; Kelder JC; Hackeng CM; Ten Berg JM
Semin Thromb Hemost; 2017 Jun; 43(4):439-446. PubMed ID: 28561235
[TBL] [Abstract][Full Text] [Related]
17. Reasons for the Failure of Platelet Function Testing to Adjust Antiplatelet Therapy: Pharmacodynamic Insights From the ARCTIC Study.
Lattuca B; Silvain J; Yan Y; Pouillot C; Cuisset T; Cayla G; Henry P; Diallo A; Elhadad S; Rangé G; Lhermusier T; Boueri Z; Motreff P; Carrié D; Vicaut E; Montalescot G; Collet JP
Circ Cardiovasc Interv; 2019 Nov; 12(11):e007749. PubMed ID: 31694410
[TBL] [Abstract][Full Text] [Related]
18. Acute stent thrombosis after primary percutaneous coronary intervention: insights from the EUROMAX trial (European Ambulance Acute Coronary Syndrome Angiography).
Clemmensen P; Wiberg S; Van't Hof A; Deliargyris EN; Coste P; Ten Berg J; Cavallini C; Hamon M; Dudek D; Zeymer U; Tabone X; Kristensen SD; Bernstein D; Anthopoulos P; Prats J; Steg PG
JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):214-220. PubMed ID: 25616927
[TBL] [Abstract][Full Text] [Related]
19. Platelet-Derived Thrombogenicity Measured by Total Thrombus-Formation Analysis System in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Kikuchi S; Tsukahara K; Ichikawa S; Abe T; Minamimoto Y; Kimura Y; Akiyama E; Nakayama N; Okada K; Matsuzawa Y; Konishi M; Maejima N; Iwahashi N; Hibi K; Kosuge M; Ebina T; Tamura K; Kimura K
Circ J; 2020 May; 84(6):975-984. PubMed ID: 32188836
[TBL] [Abstract][Full Text] [Related]
20. Fentanyl Delays the Platelet Inhibition Effects of Oral Ticagrelor: Full Report of the PACIFY Randomized Clinical Trial.
Ibrahim K; Shah R; Goli RR; Kickler TS; Clarke WA; Hasan RK; Blumenthal RS; Thiemann DR; Resar JR; Schulman SP; McEvoy JW
Thromb Haemost; 2018 Aug; 118(8):1409-1418. PubMed ID: 29972861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
